CHOLIC ACID ( DrugBank: Cholic Acid )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
20	副腎白質ジストロフィー	2
234	ペルオキシソーム病（副腎白質ジストロフィーを除く。）	3
265	脂肪萎縮症	1
310	先天異常症候群	1

20. 副腎白質ジストロフィー

臨床試験数 : 61 / 薬物数 : 90 - (DrugBank : 31) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 126

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00004442 (ClinicalTrials.gov)	September 1997	18/10/1999	Study of Bile Acids in Patients With Peroxisomal Disorders		Infantile Refsum's Disease;Zellweger Syndrome;Bifunctional Enzyme Deficiency;Adrenoleukodystrophy	Drug: chenodeoxycholic acid;Drug: cholic acid;Drug: ursodiol	Children's Hospital Research Foundation University of Cincinnati	Children's Hospital Medical Center, Cincinnati	Terminated	N/A	5 Years	Both	25	N/A	NULL
2	NCT00007020 (ClinicalTrials.gov)	January 1992	6/12/2000	Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid	Investigation in the Pathogenesis of Liver Disease in Patients With Inborn Errors of Bile Acid Metabolism	Infantile Refsum's Disease;Zellweger Syndrome;Adrenoleukodystrophy;Peroxisomal Disorders;Cholestasis	Drug: Cholic Acids	Travere Therapeutics, Inc.	Children's Hospital Medical Center, Cincinnati	Completed	N/A	N/A	All	85	Phase 3	United States

234. ペルオキシソーム病（副腎白質ジストロフィーを除く。）

臨床試験数 : 39 / 薬物数 : 35 - (DrugBank : 12) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 45

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00004442 (ClinicalTrials.gov)	September 1997	18/10/1999	Study of Bile Acids in Patients With Peroxisomal Disorders		Infantile Refsum's Disease;Zellweger Syndrome;Bifunctional Enzyme Deficiency;Adrenoleukodystrophy	Drug: chenodeoxycholic acid;Drug: cholic acid;Drug: ursodiol	Children's Hospital Research Foundation University of Cincinnati	Children's Hospital Medical Center, Cincinnati	Terminated	N/A	5 Years	Both	25	N/A	NULL
2	NCT00007020 (ClinicalTrials.gov)	January 1992	6/12/2000	Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid	Investigation in the Pathogenesis of Liver Disease in Patients With Inborn Errors of Bile Acid Metabolism	Infantile Refsum's Disease;Zellweger Syndrome;Adrenoleukodystrophy;Peroxisomal Disorders;Cholestasis	Drug: Cholic Acids	Travere Therapeutics, Inc.	Children's Hospital Medical Center, Cincinnati	Completed	N/A	N/A	All	85	Phase 3	United States
3	EUCTR2010-022046-25-NL (EUCTR)		27/10/2010	Cholic acid treatment in Peroxisomal Biogenesis Disorders (Zellweger spectrum): biochemical and clinical effects. - Cholic acid in Zellweger	Cholic acid treatment in Peroxisomal Biogenesis Disorders (Zellweger spectrum): biochemical and clinical effects. - Cholic acid in Zellweger	Peroxisomal biogenesis disorder Synonym: Zellweger spectrum disorderThis syndrome encompasses a spectrum of severity in symptomsPreviously the disorder was subdivided into three disorders based on the severity of symptoms; Infantile Refsum disease (IRD) is the mildest form, neonatal adrenoleucodystrofia (NALD) has more severe symptoms and Zellweger syndrome has the most severe clinical symptoms. MedDRA version: 12.1;Level: LLT;Classification code 10053706;Term: Zellweger syndrome MedDRA version: 12.1;Classification code 10038275;Term: Refsum's disease	Product Name: cholic acid Product Code: CA INN or Proposed INN: Cholic Acid Other descriptive name: CHOLIC ACID	Department of Pediatric Gastroenterology, Academic Medical Centre	NULL	NA			Female: yes Male: yes		Phase 2	Netherlands

265. 脂肪萎縮症

臨床試験数 : 112 / 薬物数 : 155 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 97

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00457639 (ClinicalTrials.gov)	April 2006	4/4/2007	Cholic Acid for Hepatic Steatosis in Lipodystrophy	Phase II Study of Cholic Acid for Hepatic Steatosis in Lipodystrophy Patients	Hepatic Steatosis	Drug: Cholic Acid	University of Texas Southwestern Medical Center	FDA Office of Orphan Products Development	Completed	6 Years	70 Years	All	18	Phase 2	United States

310. 先天異常症候群

臨床試験数 : 11 / 薬物数 : 20 - (DrugBank : 10) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 7

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03720990 (ClinicalTrials.gov)	March 27, 2021	24/10/2018	Smith-Lemli-Opitz Syndrome and Cholic Acid	Smith-Lemli-Opitz Syndrome: A Pilot Study of Cholic Acid Supplementation	Smith-Lemli-Opitz Syndrome	Drug: Cholic Acid	University of Nebraska	University of Colorado, Denver;Children's Hospital Medical Center, Cincinnati;University of Pittsburgh	Active, not recruiting	2 Years	25 Years	All	12	Phase 1/Phase 2	United States

先頭へ